KT
Therapeutic Areas
GSK plc Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Blenrep (belantamab mafodotin) | Multiple Myeloma | Approved |
| Jemperli (dostarlimab) | Endometrial Cancer | Approved |
| Nucala (mepolizumab) | Severe Asthma | Approved |
| Trelegy Ellipta | COPD, Asthma | Approved |
| Shingrix | Herpes Zoster | Approved |
| Arexvy | RSV | Approved |
| GSK3844766 | HIV | Phase 1 |
| GSK3640254 | Pulmonary Arterial Hypertension | Phase 2 |
Leadership Team at GSK plc
EW
Emma Walmsley
Chief Executive Officer
IM
Iain Mackay
Chief Financial Officer
TW
Tony Wood
Chief Scientific Officer
DW
Deborah Waterhouse
Chief Executive Officer, Vaccines
LM
Luke Miels
Chief Commercial Officer
DC
Diana Conrad
Chief Legal Officer
RS
Regis Simard
President, Pharmaceuticals R&D
RC
Roger Connor
President, Global Affairs